Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

Inclusion Criteria: * women of childbearing potential must agree to use an acceptable method of birth control * clinical diagnosis of community acquired bacterial pneumonia (CABP) * PORT score of II or greater * able to generate an adequate sputum specimen * chest x-ray showing presence of new infiltrates in a lobar or multilobar distribution characteristic of bacterial pneumonia Exclusion Criteria: * history of tendon damage/disorders due to quinolone therapy * uncorrected hypokalemia * history of myasthenia gravis * intubated at the time of consent OR subject is a candidate for enrollment into the open-label S. aureus arm and has been intubated greater than 12 hours prior to randomization * mild CABP with a PORT score of less than II * viral, fungal, mycobacterial, or atypical pneumonia as a primary diagnosis * pneumonia suspected to be secondary to aspiration * primary, solitary lung abscess * healthcare-associated pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia * known bronchial obstruction or a history of postobstructive pneumonia. * primary lung cancer or another malignancy metastatic to the lungs * cystic fibrosis, known or suspected Pneumocystis jiroveci (carinii) pneumonia, or known or suspected active tuberculosis * infection that necessitates the use of a concomitant antibacterial agent in addition to study medication * systemic antibiotics within the last 96 hours before randomization, with exceptions * hospitalized for greater than 72 hours for any reason 30 days before randomization (excluding the 24 hour period before enrollment). * history of a serious hypersensitivity reaction to any quinolone including moxifloxacin. * female and pregnant, breastfeeding, or may be pregnant. Other protocol-specific eligibility criteria may apply